BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Chronic myeloid leukemia (CML) is a malignant disease affecting the WBCs of the human body through mutation of the BCR-ABL gene.1 Tyrosine kinase inhibitors (TKIs) that specifically target the activity of the oncogenic proteins encoded by the BCR-ABL gene have become the standard therapy for chronic-phase, Philadelphia-positive CML, as per international guidelines.2,3 TKI treatment has extensively changed the outcomes of CML by prolonging survival and increasing the number of patients achieving a deep molecular response (DMR).4-7